Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Insights and Trends

• According to DelveInsight’s analysis, the IC-MPGN market size was found to be ~USD 30 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) impose a significant, disruptive burden on patients and their caregivers.
• According to the registry in the UK, the minimal point prevalence is 1.3/100,000 for MPGN UK-wide.
• In 2025, there was a significant disparity in the frequency of IC-MPGN cases between children and adults in the US. Children accounted for only about 10% of the total IC-MPGN cases, while adults had a much higher prevalence, with approximately 3,400 cases reported.
• IC-MPGN is classified as idiopathic only after an exhaustive evaluation fails to identify an underlying cause, with emerging evidence suggesting that a subset of cases may be driven by dysregulation and overactivation of the alternative complement pathway.
• Diagnosis of IC-MPGN relies on a combination of histopathology, immunofluorescence, and clinical evaluation. Kidney biopsy remains the gold standard, enabling differentiation based on immune complex deposition and complement involvement.
• Medications used to slow kidney damage in IC-MPGN include ACE inhibitors and ARBs, diuretics, corticosteroids and other immunosuppressive agents, as well as lipid-lowering therapies.
• Treatment of IC-MPGN remains largely supportive, with no universally established disease-specific standard of care. Conventional management includes RAAS blockade and immunosuppressive agents in selected patients. Among targeted approaches, Apellis Pharmaceuticals (EMPAVELI) has emerged as a complement inhibitor with relevance to complement-driven renal diseases, representing a step toward mechanism-based therapy in IC-MPGN.
• The IC-MPGN pipeline is increasingly focused on modulation of the alternative complement pathway. Key emerging companies include Novartis (iptacopan) and SanegeneBio (SGB-9768). These agents target upstream regulators of complement activation, aiming to provide more precise and sustained disease control.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Size and Forecast in the 7MM

• 2025 IC-MPGN Market Size: ~USD 30 million
• IC-MPGN Growth Rate (2026–2036): 26% CAGR

DelveInsight's ‘Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the IC-MPGN, historical and forecasted epidemiology, as well as the IC-MPGN market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates IC-MPGN patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in IC-MPGN and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market

Rising Prevalence & Underlying Conditions

The increasing prevalence is driven by certain long-term infections as chronic conditions (hepatitis C), autoimmune diseases (lupus nephritis), and monoclonal gammopathy (often in adults), which drive the need for treatment.

Lack of Approved Therapies

The absence of specific, FDA-approved drugs means the market is dominated by off-label treatments, including immunosuppressants, steroids, and renin-angiotensin-aldosterone system (RAAS) inhibitors. Hence, drives the organizations to develop new therapies.

Improved Diagnostics

Better diagnostic technologies and increased awareness among clinicians for distinguishing IC-MPGN from C3 Glomerulopathy (C3G) lead to earlier, more frequent diagnoses, boosting treated patient numbers.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Understanding and Treatment Algorithm

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Overview and Diagnosis

Primary IC-MPGN is a rare, chronic kidney disorder. Excessive C3 deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. IC-MPGN can be primary (idiopathic) or secondary to underlying conditions such as infections, autoimmune diseases, or malignancies. Clinically, patients often present with proteinuria, hematuria, hypertension, and declining kidney function, and the disease may progressively lead to chronic kidney disease (CKD) or end-stage kidney failure if not adequately managed.

The diagnosis of IC-MPGN involves a combination of clinical evaluation, laboratory testing, and histopathological confirmation. Initial findings typically include proteinuria (often nephrotic range), microscopic hematuria, and reduced kidney function, along with possible low complement levels (especially C3 and C4). However, the gold standard for diagnosis is a kidney biopsy, which reveals characteristic features such as mesangial proliferation, thickened capillary walls, and immune complex deposits. Immunofluorescence microscopy demonstrates the presence of immunoglobulins (e.g., IgG) along with complement components, helping differentiate IC-MPGN from C3 glomerulopathy, where C3 deposition predominates. Approximately 50% of people living with C3G and primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis therapy.

Further details are provided in the report.

Current Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treatment Landscape

Treatment of IC-MPGN focuses on controlling blood pressure, reducing proteinuria, and managing cholesterol through a combination of pharmacologic interventions, lifestyle modifications, and emerging complement-targeted therapies.

Medications commonly used to slow kidney damage include ACE inhibitors and ARBs to lower blood pressure and reduce protein loss; diuretics to manage fluid overload and edema; corticosteroids and other immunosuppressive agents to modulate immune-mediated glomerular injury; and statins to manage cholesterol and support cardiovascular protection.

Further details related to country-based variations are provided in the report.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Unmet Needs

The section “unmet needs of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited approved therapies
2. Distinction from C3G and underlying causes 
3. High risk of progression to kidney failure
4. Diagnostic delays, and others…..

Note: Comprehensive unmet needs insights in IC-MPGN and their strategic implications are provided in the full report.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Epidemiology

Key Findings from IC-MPGN Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates, in 2025, the total number of diagnosed prevalent cases of IC-MPGN in the 7MM were  about 7,000.
• In 2025, the US accounted for the highest number of diagnosed prevalent cases of IC-MPGN, with ~3,500 cases, followed by Japan.
• According to DelveInsight’s estimates, males represent more than 50% of the total IC-MPGN cases in the US in 2025.  
• The cases of IC-MPGN are more prevalent in adults than in pediatrics.
• Although the incidence of idiopathic IC-MPGN remains unknown, the estimated global annual incidence of C3G ranges from 1 to 3 cases per million individuals. The risk of progression to kidney failure is substantial, with up to 30–35% of patients with C3G or idiopathic IC-MPGN developing kidney failure within 10 years of diagnosis.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Drug Analysis & Competitive Landscape

The IC-MPGN drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase III–II clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships, upcoming key catalysts for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the IC-MPGN treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the IC-MPGN therapeutics market.

Approved Therapies for Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Pegcetacoplan (EMPAVELI): Biogen (Apellis pharmaceuticals)and Swedish Orphan Biovitrum AB

Pegcetacoplan (EMPAVELI), developed by Apellis Pharmaceuticals, is a targeted complement component 3 (C3) therapy designed to regulate excessive activation of the complement cascade, a part of the body’s immune system. EMPAVELI is the first and only FDA-approved treatment for pediatric (12+ years) and adult patients. The VALIANT study was the largest single trial conducted in patients who were 12 years of age and older and the only study to include pediatric and adult patients, with native and post-transplant kidneys. In the study, EMPAVELI demonstrated a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits compared to placebo.  

Note: Detailed marketed therapies assessment will be provided in the final report.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Pipeline Analysis

Iptacopan (LNP023): Novartis 

Iptacopan is an oral, first-in-class, small-molecule inhibitor of complement factor B. Iptacopan is currently in a Phase III (APPARENT) study for Idiopathic IC-MPGN. It is the most advanced asset in the Novartis nephrology pipeline and has the potential to become the first targeted therapy to delay progression to dialysis in C3G9. According to the company’s February 2026 investor presentation, clinical trial data readout is anticipated in 2028..

SGB-9768: SanegeneBio

SGB-9768 is a GalNAc-conjugated experimental RNAi-based medicine designed to silence C3 mRNA in hepatocytes, thereby inhibiting complement activation, currently in Phase II clinical studies for the treatment of IC-MPGN. In a Phase I clinical trial, a single subcutaneous administration of SGB-9768 achieved dose-dependent, significant, and sustained reduction in serum C3 and inhibition of complement pathway activity, as well as a favorable safety and tolerability profile, demonstrating its best-in-class potential. Currently , the clinical trial is ongoing in China, and the company has global commercial rights. 

Note: Detailed emerging therapies assessment will be provided in the final report.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Key Players, Market Leaders and Emerging Companies

• Biogen (Apellis pharmaceuticals)Swedish Orphan Biovitrum AB
• SanegeneBio
• Novartis

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Drug Updates

• In March 2026, Biogen and Apellis Pharmaceuticals announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire Apellis.
• In February 2026, SanegeneBio announced that SGB-9768 has received Orphan Drug Designation from the US FD for the treatment of IC-MPGN.
• In July 2025, Apellis Pharmaceuticals announced that US FDA has approved EMPAVELI (pegcetacoplan) as the first treatment for primary IC-MPGN in patients 12 years of age and older, to reduce proteinuria. The approval of EMPAVELI is based on positive six-month results from Phase III (VALIANT) study.
• In November 2025, SanegeneBio announced that the results from Phase I clinical studies of SGB-9768 were presented in a poster session at the American Society of Nephrology (ASN) Kidney Week 2025.
• In December 2025, Apellis Pharmaceuticals announced that The New England Journal of Medicine (NEJM) published positive results from the Phase III (VALIANT) study investigating EMPAVELI.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Outlook

The treatment landscape of IC-MPGN is undergoing a significant transition from long-standing reliance on supportive care and broad immunosuppression toward more mechanism-based and targeted therapeutic strategies. Historically, patients were managed with renin–angiotensin system blockers, diuretics, corticosteroids, and other immunosuppressive agents.

A major turning point in the field has been the approval of pegcetacoplan (EMPAVELI), the first targeted therapy for IC-MPGN, which inhibits C3 and has demonstrated clinically meaningful reductions in proteinuria along with stabilization of kidney function, thereby validating complement inhibition as a disease-modifying approach.

In parallel, the pipeline is expanding rapidly with next-generation complement-targeted agents that aim to improve efficacy, convenience, and safety. Complement factor B inhibitors such as iptacopan are being evaluated in advanced clinical trials and represent a shift toward oral, long-term complement control strategies. Another pipeline candidate, SGB-9768 is an investigational RNA interference (siRNA) therapy. By lowering circulating C3 levels, the drug aims to prevent IC-MPGN mediated kidney damage and slow disease progression.

Overall, the launch of approved therapies and rising disease awareness are expected to drive steady growth in the 7MM IC-MPGN market from 2022–2036, with strong commercial implications for both marketed products and emerging pipelines.

• Among the 7MM, the US accounted for the largest market size of IC-MPGN. i.e., USD ~20 million in 2025.
• The entry of late to mid-stage candidates such as iptacopan (LNP023) and SGB-9768 is expected to intensify competition in the IC-MPGN treatment landscape during the latter half of the forecast period.
• EMPAVELI continues to elevate the standard of care, supported by a strong and consistent safety profile, with over 3,000 patient-years of systemic pegcetacoplan exposure.

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in IC-MPGN (2022–2036 Forecast)

The IC-MPGN market comprises Complement factor C and B inhibitors, each targeting different aspects of IC-MPGN.

• Complement factor C inhibitor: Approved therapy, Pegcetacoplan blocks central complement activation at C3, inhibiting downstream inflammatory pathways and offering a broad, mechanism-based approach to limit kidney damage in IC-MPGN.
• Complement factor B inhibitor: Emerging therapy like Iptacopan targets the alternative complement pathway by inhibiting factor B, preventing C3 convertase formation and reducing complement-driven glomerular injury in IC-MPGN.

Complement factors C and B defines the core innovation landscape in approved and emerging therapies driving pipeline growth of IC-MPGN.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the IC-MPGN drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in IC-MPGN is expected to based on clinical positioning, mechanism of action, and stage of development. Recently introduced complement-targeted therapy, such as pegcetacoplan, is projected to see moderate uptake, driven by its mechanism-based approach targeting central complement activation and the high unmet need in complement-mediated renal diseases.

In contrast, pipeline agent such as iptacopan is expected to follow a gradual to moderate uptake trajectory, reflecting its investigational status and the time required to establish robust clinical efficacy and safety data. The oral administration and targeted inhibition of the alternative pathway may support broader adoption over time, particularly if strong outcomes are demonstrated.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The United States

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report….

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Therapies Price Scenario & Trends

Pricing and analogue assessment of IC-MPGN therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

To keep up with IC-MPGN market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the IC-MPGN emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in IC-MPGN, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the Stanford University, University of Würzburg, and Cardiovascular Prevention Institute, etc. were contacted.Their opinion helps understand and validate current and emerging IC-MPGN therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in IC-MPGN.

 Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of IC-MPGN, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of IC-MPGN, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the IC-MPGN market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM IC-MPGN market.

Report Insights

• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Patient Population Forecast
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Therapeutics Market Size
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Pipeline Analysis
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Size and Trends
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treatment Addressable Market (TAM)
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Competitve Landscape
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)) Major Companies Insights
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Price Trends and Analogue Assessment
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Therapies Drug Adoption/Uptake
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Therapies Peak Patient Share Analysis

Report Assessment

• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Current Treatment Practices
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Unmet Needs
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Clinical Development Analysis
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Emerging Drugs Product Profiles
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market attractiveness
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Qualitative Analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the IC-MPGN market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of IC-MPGN?
• What are the disease risks, burdens, and unmet needs of IC-MPGN? What will be the growth opportunities across the 7MM concerning the patient population with IC-MPGN?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of IC-MPGN? What are the current guidelines for treating IC-MPGN in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the IC-MPGN market.
• Bottom‑up forecasting builds from the affected population to product forecasts, delivering a robust, data‑driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)‑enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data‑driven decisions.